Table 2:

Summary of the multivariate CPH models with age and surgical extent (subtotal, gross total resection) as covariates

Edge	Time	PFS P Value	HR	95% CI	OS P Value	HR	95% CI
EC_100%	Postbevacizumab	.009^{^a}	0.37	0.18–0.78	.046^{^b}	0.42	0.18–0.98
EC_75%	Postbevacizumab	.013^{^b}	0.33	0.13–0.79	.041^{^b}	0.34	0.12–0.96
EC_50%	Postbevacizumab	.015^{^b}	0.29	0.10–0.78	.026^{^b}	0.25	0.07–0.85
EC_25%	Postbevacizumab	.018^{^b}	0.21	0.05–0.77	.022^{^b}	0.16	0.03–0.77
FLAIR_VOL	Postbevacizumab	.872	1.000	1.000–1.000	.204	1.000	1.000–1.000
CE_VOL	Postbevacizumab	.758	1.000	1.000–1.000	.258	1.000	1.000–1.000
ΔEC_100%	Pre- and postbevacizumab	.018^{^b}	2.81	1.92–6.65	.033^{^b}	2.98	1.09–8.16
ΔEC_75%	Pre- and postbevacizumab	.039^{^b}	2.75	1.05–7.19	.050	3.06	0.99–9.39
ΔEC_50%	Pre- and postbevacizumab	.058	2.91	0.96–8.08	.054	3.54	0.97–12.88
ΔEC_25%	Pre- and postbevacizumab	.067	3.74	0.090–15.42	.056	4.76	0.95–23.64
ΔFLAIR_VOL	Pre- and postbevacizumab	.360	1.000	1.000–1.000	.487	1.000	1.000–1.000
ΔCE_VOL	Pre- and postbevacizumab	.951	1.000	1.000–1.000	.926	1.000	1.000–1.000